Article

Addition of docetaxel ups survival in esophageal and gastric cancers

Elizabeth whittington blog image

Patients whose advanced esophageal or gastric cancers return after treatment often don't have many treatment options. Currently, physicians treat patients with second-line chemotherapy, but until now, there haven't been any large studies to really back up the strategy. Fortunately, the COUGAR-02 study shows that we're on the right track. In the phase 3 study, patients with advanced cancer whose disease had progressed within six months of chemotherapy received either docetaxel or active symptom control. The addition of docetaxel (Taxotere) improved median overall survival from 3.6 months to 5.2 months, and nearly half of patients' cancers were stabilized after chemotherapy. About 20 percent of patients did experience a severe toxicity, though. In light of the results, researchers hope doctaxel will be considered a new standard of treatment for patients with advanced esophageal or gastric cancer. The results were first announced this past January at the ASCO Gastrointestinal Cancers Symposium.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Related Content